2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
Open Access
- 7 May 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 95 (9) , 675-682
- https://doi.org/10.1093/jnci/95.9.675
Abstract
Background: Some anticancer drugs inhibit thymidylate synthase (TS), a key enzyme for thymidine nucleotide biosynthesis. Cells can compensate for depleted thymidine levels by taking up extracellular thymidine via a salvage pathway. We investigated the use of 2-[11C]thymidine positron emission tomography (PET) to measure thymidine salvage kinetics in vivo in humans. Methods: Five patients with advanced gastrointestinal cancer were PET scanned both before and 1 hour after oral administration of the TS inhibitor AG337 (THYMITAQ [nolatrexed]); seven control patients were scanned twice but not treated with AG337. Thymidine salvage kinetics were measured in vivo using 2-[11C]thymidine PET and spectral analysis to obtain the standardized uptake values (SUV), the area under the time–activity curve (AUC), and the fractional retention of thymidine (FRT). Changes in PET parameters between scans in the AG337-treated and control groups were compared using the Mann–Whitney U test. The relationship between AG337 exposure and AG337-induced changes in tumor FRT and in plasma deoxyuridine levels (a conventional pharmacodynamic systemic measure of TS inhibition) was examined using Spearman’s regression analysis. Statistical tests were two-sided. Results: The between-scan change in FRT in patients treated with AG337 (38% increase, 95% confidence interval [CI] = 8% to 68%) was higher than that in control patients (3% increase, 95% CI = –11% to 17%) (P = .028). The level of AG337-induced increase in both 2-[11C]thymidine FRT and plasma deoxyuridine levels was statistically significantly correlated with AG337 exposure (r = 1.00, P = .01 for both). Conclusions: AG337 administration was associated with increased tumor tracer retention that was consistent with tumor cell uptake of exogenous 2-[11C]thymidine as a result of TS inhibition. 2-[11C]Thymidine PET can be used to measure thymidine salvage kinetics directly in the tissue of interest.Keywords
This publication has 16 references indexed in Scilit:
- Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug actionThe Lancet, 2000
- An automated radiosynthesis of 2-[]thymidine using anhydrous []urea derived from []phosgeneApplied Radiation and Isotopes, 1999
- Imaging proliferation in vivo with [F-18]FLT and positron emission tomographyNature Medicine, 1998
- Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: A feasibility studyCancer Chemotherapy and Pharmacology, 1998
- AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studiesCancer Chemotherapy and Pharmacology, 1996
- Biochemical Modulation by 5-Fluorouracil and 1-Folinic Acid of Tumor Uptake of Intra-Arterial 5-[123I]Iodo-2'-Deoxyuridine in Patients with Liver Metastases from Colorectal CancerActa Oncologica, 1996
- Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinonesJournal of Medicinal Chemistry, 1993
- Spectral Analysis of Dynamic PET StudiesJournal of Cerebral Blood Flow & Metabolism, 1993
- Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cellsBiochemical Pharmacology, 1988
- Modulation of anti-metabolite effectsBiochemical Pharmacology, 1984